A key output produced within Theme 3 of NIHR CLAHRC Oxford with potential for longer-term impact is the Musculoskeletal Health Questionnaire (MSK-HQ). The MSK-HQ is a new patient-reported outcome measure (PROM) designed to work across all musculoskeletal conditions. Since the publication of its validation study in August 2016, Theme 3 researchers have worked in partnership with Arthritis Research UK (ARUK) and researchers at Keele University to test the use of the MSK-HQ within relevant settings such as physiotherapy clinics. As a result of the work to date, ARUK now recommends the MSK-HQ as one of two PROMs (alongside the widely used EQ-5D) as the most appropriate measures for indicating the level of health-related quality of life related to clinical musculoskeletal care. ARUK’s recommendations are available online to the wider health and social care system, and they are also endorsed by NHS England. Longer term, the collaborative development and implementation of MSK-HQ can serve as a leading example of how patient-reported measures could drive quality improvement within routine clinical practice.
Since its development and validation the MSK-HQ has been licenced for use by Oxford University Innovation, the University of Oxford’s technology transfer company
Contribution of CLAHRC Oxford
Theme 3 researchers Ray Fitzpatrick and Elizabeth Gibbons worked in collaboration with researchers at Keele University to develop the measure. They also led on the development and delivery of a partnership model for implementing the MSK-HQ within clinical practice (described in a paper currently under peer review). NIHR CLAHRC Oxford has contributed directly to these outputs and impacts via salary support for the lead researcher (Elizabeth Gibbons) and programme support for the Theme 3 Lead (Ray Fitzpatrick).
What happened next?
Since its development and validation the MSK-HQ has been licenced for use by Oxford University Innovation, the University of Oxford’s technology transfer company. Arthritis Research UK currently recommends the MSK-HQ as one of two patient-reported outcome measures appropriate for assessing change in health-related quality of life in relation to clinical musculoskeletal care (e.g. whether health-related quality of life has improved between baseline measurement and six months post-treatment). ARUK’s recommendation for use of the MSK-HQ is currently endorsed by NHS England.